Despite Sirio Pharma's lower returns, reinvestment rise and ...
Despite Sirio Pharma's lower returns, reinvestment rise and higher sales are hopeful. But the persistent drop in ROCE and 58% stock slide over three years imply a need for thorough inquiry into more business basics before deciding to invest.
Sirio Pharma (SZSE:300791) Could Be Struggling To Allocate Capital
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment